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Obestatin, a 23-amino acid peptide derived from the proghrelin, has been shown to exhibit some protective and therapeutic effects
in the gut. The aim of present study was to determine the effect of obestatin administration on the course of acetic acid-induced
colitis in rats. Materials and Methods. Studies have been performed on male Wistar rats. Colitis was induced by a rectal enema
with 3.5% acetic acid solution. Obestatin was administered intraperitoneally twice a day at a dose of 8 nmol/kg, starting 24 h
after the induction of colitis. Seven or 14 days after the induction of colitis, the healing rate of the colon was evaluated. Results.
Treatment with obestatin after induction of colitis accelerated the healing of colonic wall damage and this effect was associated
with a decrease in the colitis-evoked increase in mucosal activity of myeloperoxidase and content of interleukin-1𝛽. Moreover,
obestatin administration significantly reversed the colitis-evoked decrease in mucosal blood flow and DNA synthesis. Conclusion.
Administration of exogenous obestatin exhibits therapeutic effects in the course of acetic acid-induced colitis and this effect is
related, at least in part, to the obestatin-evoked anti-inflammatory effect, an improvement of local blood flow, and an increase in
cell proliferation in colonic mucosa.
1. Introduction
Obestatin is a 23-amino acid peptide derived from pre-
proghrelin, a common prohormone for ghrelin and obestatin
[1–3].Obestatinwas originally extracted from the rat stomach
and the stomach seems to be a major source of circulating
obestatin [1, 2, 4]. Secretion of obestatin is pulsative and
displays an ultradian rhythmicity similar to ghrelin and
growth hormone [5]. In contrast to ghrelin, obestatin has
been reported to be an anorexic hormone, reducing food
intake, gastric emptying time, jejunal motility, and body
weight gain [2, 3].
Previous studies have shown that pretreatment with
ghrelin, an alternative product of posttranslational processing
of preproghrelin, protects gastric mucosa against damage
evoked by different noxious factors [6–8] and inhibits the
development of experimental acute pancreatitis [9, 10].
Moreover, apart from its protective effect, ghrelin exhibits
therapeutic effect in the gut. It accelerates the healing of
gastric [11], duodenal [11, 12] and oral ulcers [13], and colonic
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inflammation [14, 15]. Therapeutic effect of ghrelin has been
also shown in experimental models of acute pancreatitis [16–
19].
In the case of obestatin, there are studies which have
shown that also this peptide exhibits some protective and
therapeutic effects in the gut [3]. It has been demonstrated
so far that preventive administration of obestatin inhibits the
development of cerulein- and ischemia/reperfusion-induced
acute pancreatitis [20, 21]. Moreover, Granata et al. have
reported that obestatin promotes survival of pancreatic islets,
especially 𝛽-cell [22]. In the stomach, it has been shown
that treatment with obestatin accelerates the healing of acetic
acid-induced gastric ulcers [23]. Moreover, previous studies
have suggested that endogenous and exogenous obestatin
may affect or be related to the development of colitis.
Alexandridis et al. have found that the ratio of serum level
of obestatin to ghrelin in patients with active inflammatory
bowel disease (IBD) is significantly lower than in patients
with remission [24]. This observation was confirmed by Jung
et al. and they have suggested that the obestatin/ghrelin ratio
may be useful in monitoring of remission in the course of
IBD [25]. Furthermore, one experimental study has shown
protective effect of obestatin in the colon. Pamukcu et al. have
reported that administration of obestatin before and during
the development of dextran sodium sulfate-induced colitis
reduces the severity of this inflammation [15].
The objective of the present research was to determine
whether administration of obestatin after the development of
colitis exhibits therapeutic effect in this disease.
2. Material and Methods
2.1. Animals and Treatment. Studies were performed on 80
male Wistar rats weighing 270–320 g and were conducted
following the experimental protocol approved by the 1st Local
Committee of Ethics for the Care and Use of Laboratory
Animals in Cracow (Permit number 2/2013 released on
January 16, 2013). During the experiments animals were
kept in cages placed in room temperature with a 12 h light-
darkness cycle. Animals were fasted, with free access to water,
for 18 h prior to induction of colitis. Later, water and food
were available ad libitum.
The animals were randomly divided into four groups: (1)
control ratswithout colitis induction treated intraperitoneally
(i.p.) with saline; (2) rats without colitis induction treated i.p.
with obestatin; (3) rats with colitis treated i.p. with saline; (4)
rats with colitis treated i.p. with obestatin.
In the rats anesthetized with pentobarbital (30mg/kg i.p.,
Vetbutal, Biowet, Puławy Poland), colitis was induced by
a rectal enema with 1mL of 3.5% (v/v) acetic acid diluted
in saline. Acetic acid solution was administered through a
polyethylene catheter inserted into the rectum. There are
different models of acetic acid-induced colitis and the tip
of catheter can be positioned from 1.2 [26] to 8 cm [27]
proximal to the anus verge. For this reason we have chosen
an intermediate depth of catheter insertion, 4.5 cm from the
anus. Rats without induction of colitis obtained rectal enema
with an aqueous saline solution administered at the same
manner as a solution of acetic acid in animals with induction
of colitis.
Starting 24 hours after a rectal enema with saline or
acetic acid, the rats were treated with saline (groups 1 and
3) or obestatin (groups 2 and 4) administered i.p. twice
a day. Rat obestatin (Yanaihara Institute, Shizuoka, Japan)
was given at a dose of 8 nmol/kg. This dose was chosen
because previous studies have shown that obestatin given at
a dose 8 nmol/kg exhibits strong and repeatable therapeutic
effect in the healing of chronic gastric ulcers [23]. Rats from
each experimental group were randomly divided into two
subgroups. In the first subgroup, the healing rate of the colon
was evaluated 7 days after the acetic acid enema. In the
second subgroup evaluation was performed 7 days later. Each
subgroup consisted of 10 animals.
2.2. Measurement of Colonic Blood Flow and Colonic Damage.
At the end of the experiments, animals were anesthetized
again with pentobarbital. After opening the abdominal cavity
and exposure of the colon, the rate of colonic blood flow
was measured using laser Doppler flowmeter (PeriFlux 4001
Master monitor, Perimed AB, Järfälla, Sweden), in accor-
dance with the methodology described before [28]. The
measurement of mucosal blood flow was performed every
time in five parts of the descending and sigmoid colon and
themain value of five records was expressed as the percentage
of the value obtained in the animals from the control group.
After the measurement of colonic blood flow, anesthetized
animals were euthanized by exsanguination from the abdom-
inal aorta. Then, the area of mucosal damage was measured,
using a computerized planimeter (Morphomat, Carl Zeiss,
Berlin, Germany), in accordance with the method described
earlier [12]. Briefly, the large bowel was removed from the
body, opened along of its long axis on the side opposite to
the mesentery, and washed with ice-cold saline. The colon
sampleswere flattened and carefully sandwiched between two
layers of transparent plastic folder. The area of damage was
measured by tracing its perimeter.
2.3. Biochemical Analysis. The dynamics of DNA replication
in the colon mucous membrane was marked with radioiso-
topemethod throughmeasurement of tritium-labeled thymi-
dine incorporation into DNA, according to the methodology
described before [29]. Amucousmembrane sample was frag-
mented with scissors, subsequently, the tissue was incubated
in 37∘C for 45 minutes in 2mL of nutritive solution con-
taining tritium-marked thymidine ([6-3H] thymidine, 20–
30Ci/mmol; Institute for Research, Production and Applica-
tion of Radioisotopes, Prague, Czech Republic), with activity
of 8𝜇Ci/mL. Incorporation of [3H]-thymidine into DNAwas
determined by counting 0.5mLDNA-containing supernatant
in liquid scintillation system. The rate of DNA synthesis was
expressed as disintegration per minute [3H]-thymidine per
microgram DNA (dpm/𝜇g DNA).
Samples of the colonic mucosa, in which the concen-
tration of interleukin-1𝛽 was measured, were homogenized
in phosphate buffer at 4∘C. Then the homogenate was
centrifuged and the concentration of interleukin-1𝛽 in the
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Figure 1: Effect of saline or obestatin given intraperitoneally for
7 or 14 days on the area of colonic lesions in rats without or with
acetic acid-induced colitis. Mean value ± SEM. 𝑁 = 10 animals in
each experimental group and each time of observation. a𝑃 < 0.05
compared to control at the same time of observation; b𝑃 < 0.05
compared to colitis plus saline at the same time of observation.
supernatant was determined using the Rat IL-1𝛽 Platinum
Elisa (Bender MedSystem GmbH, Vienna, Austria). The
concentration of interleukin-1𝛽 of the colonic mucosa was
expressed in nanograms per 1 gram of tissue.
Biopsy samples for measurement of mucosal myeloper-
oxidase activity were homogenized in ice-cold potassium
phosphate and, until the marking was done, stored at the
temperature of−60∘C.Markingmyeloperoxidase activity was
performed with the use of a modification of the method
described by Bradley et al. [30]. Results obtained in units per
gram of tissue were finally expressed as a percentage of the
value observed in the control group.
2.4. Statistical Analysis. Statistical analysis of the data was
carried out by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s multiple comparison test using GraphPad-
Prism (GraphPad Software, San Diego, CA, USA). Differ-
ences were considered to be statistically significant when 𝑃
was less than 0.05.
3. Results
Figure 1 shows the influence of obestatin administration on
the healing of acetic acid-induced mucosal damage in the
colon. In saline- and obestatin-treated rats without induction
of colitis no mucosal damage was observed. In saline-treated
rats, 7 days after the induction of colitis, the mucosal damage
area was 16.2 ± 0.8mm2, whereas 7 days later it was reduced
to 6.8 ± 0.4mm2 as a result of spontaneous regeneration.
Treatment with obestatin for 7 days after administration of
acetic acid accelerated a reduction in the mucosal damage
area by 35.2%. After the next 7 days of treatment with
obestatin, the area of colonic damage was reduced by around
78% when compared to lesions observed in the animals
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Figure 2: Effect of saline or obestatin given intraperitoneally for
7 or 14 days on the rate of DNA synthesis in colonic mucosa in
rats without or with acetic acid-induced colitis. Mean value ± SEM.
𝑁 = 10 animals in each experimental group and each time of
observation. a𝑃 < 0.05 compared to control at the same time of
observation; b𝑃 < 0.05 compared to colitis plus saline at the same
time of observation.
treated with saline. The healing promoting effect of obestatin
was statistically significant at both periods of observation,
after 7 and 14 days of obestatin administration (Figure 1).
In the rats without induction of colitis, administration
of obestatin at a dose used failed to affect significantly DNA
synthesis in colonic mucosa (Figure 2). Induction of colitis
by an enema with acetic acid led to reduction in mucosal
DNA synthesis in the colon. DNA synthesis in the colonic
mucosa was significantly reduced by around 45 and 32% at
the 7th and 14th day after induction of colitis, respectively.
Treatment with obestatin partly reversed the colitis-evoked
reduction in DNA synthesis in the colonic mucosa and this
effect was statistically significant after 14 days of obestatin
administration (Figure 2).
In the groups of animals without induction of colitis,
intraperitoneal administration of obestatin for 7 or 14 days
failed to affect mucosal blood flow in the colon (Figure 3).
In the rats with colitis, 7 days after an enema with acetic
acid, blood flow through the colonic mucosa was signifi-
cantly reduced by around 50%, when compared to the value
observed in the control animals without colitis. After the next
seven days, mucosal blood flow in the colon of the animals
with colitis was almost fully restored and no significant
difference was observed in comparison to a value in control
group of animals. In the rats with colitis, administration of
obestatin caused an improvement of mucosal blood flow in
the colon and this effect was statistically significant at the 7th
day after the induction of colitis (Figure 3).
In the rats without colitis, administration of obestatin
for 7 or 14 days at the dose used was without any effect
on mucosal concentration of interleukin-1𝛽 (IL-1𝛽) in the
colon (Figure 4). Induction of colitis significantly increased
mucosal concentration of IL-1𝛽 in the colon. As shown in
Figure 4, ratswith colitis demonstratedmore than 10-fold and
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Figure 3: Effect of saline or obestatin given intraperitoneally for 7
or 14 days on mucosal blood flow in the colon rats without or with
acetic acid-induced colitis. Mean value ± SEM. 𝑁 = 10 animals in
each experimental group and each time of observation. a𝑃 < 0.05
compared to control at the same time of observation; b𝑃 < 0.05
compared to colitis plus saline at the same time of observation.
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Figure 4: Effect of saline or obestatin given intraperitoneally for
7 or 14 days on interleukin-1𝛽 concentration in colonic mucosa
in rats without or with acetic acid-induced colitis. Mean value ±
SEM. 𝑁 = 10 animals in each experimental group and each time
of observation. a𝑃 < 0.05 compared to control at the same time of
observation; b𝑃 < 0.05 compared to colitis plus saline at the same
time of observation.
6-fold increase in this parameter at the 7th day and 14th after
induction of colitis, respectively. Administration of obestatin
at the dose used partly reversed the colitis-evoked increase in
mucosal concentration of IL-1𝛽 and this effectwas statistically
significant in both periods of observation (Figure 4).
Administration of obestatin for 7 or 14 days was without
effect onmucosalmyeloperoxidase activity in the colon in the
rats without colitis induction (Figure 5). In rats treated with
saline after induction of colitis, 7 days after induction of this
inflammation, myeloperoxidase activity in colonic mucosa
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Figure 5: Effect of saline or obestatin given intraperitoneally for 7
or 14 days on myeloperoxidase activity in colonic mucosa in rats
without or with acetic acid-induced colitis. Mean value ± SEM.
𝑁 = 10 animals in each experimental group and each time of
observation. a𝑃 < 0.05 compared to control at the same time of
observation; b𝑃 < 0.05 compared to colitis plus saline at the same
time of observation.
was increased by 318%. Also, after the next 7 days, almost 2-
fold increase in myeloperoxidase activity was still observed
in colonic mucosa in rats with colitis treated with saline.
Treatment with obestatin reduced the colitis-evoked increase
inmyeloperoxidase activity in the colonicmucosa.This effect
was statistically significant in both periods of observation, 7
and 14 days after induction of (Figure 5).
4. Discussion
In this study, we have investigated the influence of treatment
with obestatin on the course of acetic acid-induced colitis.We
have found that intraperitoneal administration of obestatin
given at the dose 8 nmol/kg significantly accelerates the
recovery of colonic wall integrity in rats with this model
of experimental colitis. Maintaining the integrity of the
digestive tract mucous membrane depends on preservation
of balance between proliferation and loss of epithelial cells.
A disruption of that balance, as a result of a decrease in
cell proliferation, apoptosis, and/or increased cell loss, leads
to mucosal atrophy and/or ulceration [31, 32], whereas an
increase in cell division may lead to mucosal hypertrophy.
On the other hand, stimulation of cell proliferation typically
leads to increase in the protection of the digestive tract
mucous membrane against damaging factors and accelerates
the healing of mucosal damage [33–35]. Synthesis of DNA
is an indispensable process for mitosis to take place [36].
Therefore, assessment of DNA synthesis dynamics through
measurement of incorporation of tritium-marked thymidine
into cellular DNA reflects vitality of cells and cellular division
dynamics.
In our present study, we have found that administration
of obestatin in animals without induction of colitis failed
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to significantly affect mucosal DNA synthesis in the colon.
This leads to the conclusion that, in animals with normal
colonic mucous membrane, treatment with obestatin given
at the dose of 8 nmol/kg does not stimulate DNA synthesis in
colonic mucosa and therefore this peptide seems to be safe
and does not bring a risk of hyperplasia and hypertrophy
of colonic mucosa. On the other hand, administration of
obestatin in rats with colitis led to a considerable improve-
ment of mucosal DNA synthesis in the colon. This observa-
tion indicates that therapeutic effect of obestatin in the course
of acetic acid-induced colitis is, at least in part, a result of
increase in cell vitality in colonic mucosa.
Another factor that plays a role in maintaining mucosal
integrity is suitable, adequate for the demand, organ blood
flow. The important role of vascular mechanisms in pro-
tection and healing of gastrointestinal mucosa has been
previously described [37–39]. Experimental studies have
demonstrated that exposure of the stomach to damaging
factors leads to small mucosal damage, as long as a sufficient
blood flow is maintained. A similar significance of suffi-
cient blood flow in maintaining mucosal integrity was also
demonstrated in other parts of the digestive tract, including
the oral cavity [13], esophagus [38], duodenum [11, 12] and
colon [39]. In our present study, we have observed that
intrarectal administration of acetic acid solution decreases
mucosal blood flow in the colon. Seven days after induction
of colitis mucosal blood flowwas decreased by around 50% in
comparison with a value observed in control group without
colitis. After the next 7 days, blood flow in colonic mucosa in
rats with colitis was still lower than in control group, but this
difference was statistically insignificant.
Administration of obestatin in the dose used did not
exhibit any influence on blood flow in the colonic mucous
membrane in animals without colitis. In contrast to that,
administration of obestatin in animals with colitis led to a
significant improvement in blood flow in the colonic mucous
membrane, and this effect was statistically significant at the
7th day after induction of colitis. After the next 7 days a value
of blood flow in rats with colitis treated with obestatin was
similar to that recorded in control animals without colitis.
Moreover, this obestatin-evoked improvement of mucosal
blood flow was connected with a decrease in the area
and severity of colonic mucosal damage. This observation
indicates that therapeutic effect of obestatin in acetic acid-
induced colitis involves an improvement of mucosal blood
flow in the large bowel.
The next interesting finding originated from our present
study is the influence of intraperitoneal administration of
obestatin on the concentration of interleukin-1𝛽 (IL-1𝛽)
and myeloperoxidase activity in colonic mucosa of animals
with colitis. Activation of inflammatory cells with subse-
quent release of proinflammatory cytokines is responsible
for intensity of local and systemic inflammatory response
[40]. Between proinflammatory cytokines, IL-1𝛽 plays a
fundamental role in the initiation of biochemical cascade
of inflammation [40–45]. Results obtained in our present
study have demonstrated that acetic acid-induced colitis led
to a tenfold and sixfold increase in IL-1𝛽 concentration in
colonic mucosa at the 7th an 14th day after induction of this
inflammation, respectively. Intraperitoneal administration of
obestatin partially but significantly reduced that increase. On
the other hand, administration of obestatin failed to affect IL-
1𝛽 concentration in the mucous membrane in rats without
colitis.
Myeloperoxidase (MPO) is an enzyme which is present
in azurophilic granules of neutrophil granulocytes. Antimi-
crobial function of neutrophils is related, among others, to
their possibility to generate reactive oxygen species (ROS)
during the respiratory burst [46].On the other hand, excess of
ROS leads to oxidative damage of own tissues on cellular and
subcellular level resulting in destruction of proteins, nucleic
acids, and lipids [46–49]. MPO is released by activated
neutrophils and reflects the degree of tissue infiltration by
those granulocytes [46, 50].Those data are in agreement with
our present observation. Seven days after rectal enema with
acetic acid, we have observed a threefold increase in MPO
activity in the colonic mucous membrane in rats treated with
saline. After the next 7 daysmucosal activity ofMPO in colon
of rats with colitis was still significantly increased above a
level observed in control rats without induction of colitis.
Intraperitoneal administration of obestatin in animals with
acetic acid-induced colitis caused a considerable decrease in
colonic MPO activity. In contrast to that, mucosal activity
of MPO in the colon of rats without colitis was low and
administration of obestatin was without effect on colonic
MPO activity in those rats.
Our findings mentioned above concerning the inhibitory
effect of treatment with obestatin on IL-1𝛽 concentration and
MPO activity in colonic mucosa in rats with acetic acid-
induced colitis indicate that the healing promoting effect
in this kind of colitis is, at least in part, related to anti-
inflammatory properties of obestatin. On the other hand,
obestatin failed to affect mucosal IL-1𝛽 concentration and
MPO activity in the colon of rats without induction of
colitis. This observation suggests that obestatin does not
disturb the immune system in normal circumstances, without
inflammation.
As stated in the introduction, ghrelin and obestatin are
peptides encoded by the same gene and derived from a
common prohormone [1–3]. Ghrelin exhibits protective and
therapeutic effect in various organs and experimental models
of organ damage [6–19]. Data on the effects of obestatin
are less numerous. Previous studies have demonstrated that
this peptide demonstrates protective effect in the large bowel
and its earlier application reduces damage in colitis induced
by dextran sodium sulfate (DSS) [15]. Our present studies
have shown that obestatin also exhibits a therapeutic effect in
the course of colitis and administration of this peptide after
the development of acetic acid-induced colitis accelerates the
healing of inflammation. Differences between ghrelin and
obestatin are based on their action mechanisms. Ghrelin acts
directly via activation of GHS-R receptor and indirectly via
a release of growth hormone and IGF-1 [2, 3, 51]. In the
case of obestatin, its receptor is still unknown. Initially it
was thought that obestatin acts by binding to the G protein-
coupled receptor 39 (GRP39) [1], but later studies do not seem
to confirm this hypothesis [52]. Also there is another effect
of these peptides on food intake. Ghrelin stimulates food
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intake, whereas, in the case of obestatin, its inhibitory effect
on appetite has been postulated [1–3].
There are numerous experimental models of inflamma-
tory bowel disease, because each of these models is not
perfect and does not fully meet the clinical condition. DSS-
induced colitis is reproducible and one of widely used animal
models of IBD. DSS mainly affects the large bowel, but some
studies have reported that DSS also affects the distal parts
of small intestine [27]. In mice or rats, administration of
DSS causes hematochezia, body weight loss, shortening of
intestine, mucosal ulcers, and infiltration of neutrophils [53].
DSS causes erosion with complete loss of surface epithelium
because of its deleterious effect on epithelial cells [27]. Acetic
acid-induced colitis is an animal model of colitis that shows
close resemblance to human IBD in terms of pathogenesis,
morphological features, and inflammatory factors involved
in this kind of inflammation [27]. Intrarectal enema with
acetic acid solution causes inflammation characterized by
neutral infiltration into intestinal tissue, massive necrosis of
mucosal and submucosal tissues, edema, vascular dilatation,
and submucosal ulceration.Those findings are similar to that
observed in human colitis [27].
In conclusion, we can say that treatment with obestatin
accelerates the healing of acetic acid-induced colitis and
this effect seems to be related to the obestatin-evoked anti-
inflammatory effect, an improvement of local mucosal blood
flow, and an increase in cell proliferation in colonic mucosa.
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behavior in rats subjected to gastrectomy or gastric bypass
surgery,” European Surgical Research, vol. 40, no. 3, pp. 279–288,
2008.
[5] P. Zizzari, R. Longchamps, J. Epelbaum, and M. T. Bluet-Pajot,
“Obestatin partially affects ghrelin stimulation of food intake
and growth hormone secretion in rodents,” Endocrinology, vol.
148, no. 4, pp. 1648–1653, 2007.
[6] V. Sibilia, G. Rindi, F. Pagani et al., “Ghrelin protects against
ethanol-induced gastric ulcers in rats: studies on the mecha-
nisms of action,” Endocrinology, vol. 144, no. 1, pp. 353–359,
2003.
[7] T. Brzozowski, P. C. Konturek, S. J. Konturek et al., “Exogenous
and endogenous ghrelin in gastroprotection against stress-
induced gastric damage,” Regulatory Peptides, vol. 120, no. 1–3,
pp. 39–51, 2004.
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[23] A. Dembiński, Z. Warzecha, P. Ceranowicz et al., “Adminis-
tration of obestatin accelerates the healing of chronic gastric
ulcers in rats,”Medical ScienceMonitor, vol. 17, no. 8, pp. BR196–
BR200, 2011.
[24] E. Alexandridis, A. Zisimopoulos, N. Liratzopoulos, I. Katsos,
K. Manolas, and G. Kouklakis, “Obestatin/ghrelin ratio: a new
activity index in inflammatory bowel diseases,” Inflammatory
Bowel Diseases, vol. 15, no. 10, pp. 1557–1561, 2009.
[25] J. Y. Jung, J. B. Jeong, J. W. Kim et al., “Circulating ghrelin levels
and obestatin/ghrelin ratio as a marker of activity in ulcerative
colitis,” Intestinal Research, vol. 13, no. 1, pp. 68–73, 2015.
[26] B. R. MacPherson and C. J. Pfeiffer, “Experimental production
of diffuse colitis in rats,” Digestion, vol. 17, no. 2, pp. 135–150,
1978.
[27] P. K. Randhawa, K. Singh, N. Singh, and A. S. Jaggi, “A review
on chemical-induced inflammatory bowel disease models in
rodents,” Korean Journal of Physiology and Pharmacology, vol.
18, no. 4, pp. 279–288, 2014.
[28] K. Johansson, H. Ahn, J. Lindhagen, and O. Lundgren, “Tissue
penetration and measuring depth of laser doppler flowmetry
in the gastrointestinal application,” Scandinavian Journal of
Gastroenterology, vol. 22, no. 9, pp. 1081–1088, 1987.
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